I would like to thank Lynn Bergeson, Bergeson & Campbell, P.C.,  Richard Canady, PhD DABT, Senior Advisor, McKenna, Long & Aldridge,  LLP, and Philip Lippel, PhD for their contributions to this summary.
I would like to share the following nanotechnology articles with our  community:
What’s up with nanotech? 
http://www.boston.com/business/technology/articles/2010/03/29/
nanotechnologys_small_wonders_opening_new_frontiers/
U.S. lead in nanotech eroding, report finds 
http://www.washingtonpost.com/wp-dyn/content/article/2010/03/25/AR2010032501796.html
NanoBusiness Alliance to Present 3rd Annual Nano Renewable Energy  Summit in Denver, CO, May 24-25, 2010 
http://www.businesswire.com/portal/site/home/permalink/?ndmViewId=news_view&newsId=20100331005983&newsLang=en
Forbes Wolfe Emerging Tech 
http://www.forbeswolfe.com/
The NanoBusiness Alliance’s (NbA) Washington, DC Roundtable on March  15-17, 2010, was a huge success.  Below is a summary of the NbA Federal  Roundtable on March 17, 2010.
Convened in Foley & Lardner LLP’s http://www.foley.com/home.aspx lovely conference room overlooking the Potomac River from the office’s  Georgetown perch, the day-long Federal Roundtable was intended to  familiarize NbA members and supporters with a detailed and informative  overview of all aspects of federal oversight of nanotechnology.   Specifically, the NbA identified three meeting objectives: stimulate  dialogue between NbA members and federal agencies; brief members on the  latest regulatory policy/impending regulatory actions and federal  research initiatives; and familiarize NbA members with federal product  approval authorities and processes and innovation strategies, with an  emphasis on pending developments.  The agenda is available online http://www.enobis.com/pdfdocs/NbAagenda.pdf.
I www.vincentcaprio.org,  Executive Director of the NanoBusiness Alliance, introduced the first  substantive panel, moderated by Richard Canady, PhD DABT, Senior  Advisor, McKenna, Long & Aldridge, LLP.  The session, titled  Regulatory Policy Movement for Nano – Cross-Agency and International  Perspectives, featured presentations by Travis Earles, Assistant  Director for Nanotechnology, Office of Science and Technology Policy  (OSTP), Executive Office of the President.  Travis reviewed the state of  the National Nanotechnology Initiative, noting that continued growth in  both overall funding (projected at $1.7 B for 2011) and environmental,  safety and health research ($117 M). He told the audience to keep an eye  out for more details on the newly announced NNI Signature Initiatives.  Travis noted that the Administration is working hard to ensure clear  regulatory pathways for innovators. A new high-level interagency task  force on emerging technologies will look at this and other issues  affecting commercialization.  Dr. Shaun Clancy presented a PowerPoint  presentation available online, http://www.enobis.com/pdfdocs/clancy.pdf titled the Importance of Policy and International Activities to NbA  Companies.  The presentation reviewed key domestic and international  policy, standard-setting, and regulatory initiatives pertinent to NbA  members, and explained the reasons why early and consistent engagement  in these activities is essential for sound policy setting and effective  product stewardship.
Next Dr. Celia I. Merzbacher, Vice President for Innovative  Partnerships, Semiconductor Research Corporation, provided a very  informative PowerPoint presentation, available online, http://www.enobis.com/pdfdocs/merzbacher.pdf titled Nanoelectronics Research Initiative:  How Public Private  Partnerships Add Value.  Dr. Merzbacher described how SRC member  companies and federal agencies cooperate, through the NRI, on long-range  research to ensure that Moore’s Law will continue. Given Dr.  Merzbacher’s current industry role and former position with OSTP, her  insights into what makes for successful public-private partnerships were  targeted, informative, and very useful.
The next panel was moderated by Charles M. Auer, Charles Auer &  Associates, LLC, titled Chemical and Consumer Product Risk Management  Policy and Regulatory Actions.  Charlie was Director of the U.S.  Environmental Protection Agency’s (EPA) Office of Pollution Prevention  and Toxics until early 2009, and was responsible for managing EPA’s  regulatory initiatives pertinent to nanoscale materials, among many  other chemical regulatory initiatives.  Charlie was also deeply engaged  in Organization for Economic Cooperation and Development (OECD)  initiatives dealing with nanotechnology and other chemical management  initiatives, and continues to engage in OECD matters in private  practice.  Charlie’s first two speakers discussed current regulatory  approaches. First up was Bill Jordan, from EPA’s Office of Pesticide  Programs, who spoke about how the Federal Insecticide, Fungicide, and  Rodenticide Act (FIFRA) applies to nanomaterials with pesticidal or  antimicrobial properties.  Next, Jim Alwood, EPA Chemical Control  Division, gave a presentation, available online, http://www.enobis.com/pdfdocs/alwood.pdf titled TSCA Nanotechnology Regulations at EPA.  The presentation  provided an up-to-the-minute review of regulatory initiatives under the  Toxic Substances Control Act (TSCA) pertinent to most other nanoscale  materials. Finally, Dr. Jeff Morris, EPA Office of Research and  Development, described EPA’s long-term research program to develop new  methods for integrating safety and environmental impact studies of  nanomaterials into a full lifecycle assessment, covering design,  development, use, and disposal. He emphasized the collaborative nature  of this process, stating that everyone in the room needed to work on it  together, and noted that EPA has commissioned a National Acadamies study  to help plan the effort.  Dr. Morris’ excellent PowerPoint  presentation, Future Considerations for Nanotechnology EHS: Informing  Policy and Regulatory Decisions, is available online http://www.enobis.com/pdfdocs/morris.pdf. It provides a compelling basis for understanding EPA’s need for data  to inform the Agency’s risk management decision-making efforts.
The next panel focused on nanotechnology policy and guidance  developments pertinent to the U.S. Food and Drug Administration (FDA).   Foley & Lardner’s David Rosen, Co-Chair of the Life Sciences  Industry Team at the firm, moderated the session. David introduced Dr.  Mitchell A. Cheeseman, Deputy Director of the Office of Food Additive  Safety, Center for Food Safety and Applied Nutrition, who discussed  FDA’s efforts in this area.  Mitch’s PowerPoint presentation, available  online, http://www.enobis.com/pdfdocs/cheeseman.pdf titled  Regulatory Hurdles for Nanotechnology, provided a useful outline of the  challenges regulated entities face in obtaining approvals for  food-related products.  Joining Mitch on the panel was Dr. Subhas G.  Malghan, Deputy Director for Program Policy and Evaluation, Office of  Science and Engineering Laboratories, Center for Devices and  Radiological Health.  Subhas walked through a PowerPoint presentation,  available online, http://www.enobis.com/pdfdocs/malghan.pdf titled  Science and Regulatory Issues Relevant to Devices Containing Nanoscale  Materials, which reviewed issues pertinent to medical devices approvals.  The third panelist was Larry Tamarkin, CEO of CytImmune. Larry  described his company’s anticancer therapeutics. CytImmune has worked  closely with the National Cancer Institute’s Nanotechnology  Characterization Laboratory to develop data supporting FDA product  approval, and has completed Phase I clinical trials for their lead  product.
Following a luncheon break, the Federal Roundtable reconvened with a  panel discussion on workplace and worker protection issues moderated by  Dr. Sam Brauer.  Sam introduced David O’Connor, Director, Office of  Chemical Hazards, Occupational Safety and Health Administration (OSHA).   David’s PowerPoint presentation, available online, http://www.enobis.com/pdfdocs/oconnor.pdf titled Nanomaterials: OSHA’s Approach to Protecting Workers from  Potential Hazards, provides a useful overview of OSHA’s approach to nano  workplace safety. Dr. O’Connor noted that OSHA’s general mandate is to  ensure that workplaces are free from recognized hazards that could cause  death or serious harm. Nanotech manufacturers are certainly included in  this charge, but there have been no nano-specific actions to date. OSHA  enforces Permissible Exposure Limits for many materials; in the absence  of specific information about the hazards of nanoscale versions of a  material, these are legally applicable although it is not generally  known if they are protective. General requirements for the use of  personal protective equipment, including respirators, should of course  be followed. Dr. Charles A. Geraci, National Institute for Occupational  Safety and Health, Centers for Disease Control and Prevention  (NIOSH/CDC) spoke next.  Chuck gave a PowerPoint presentation, available  online, http://www.enobis.com/pdfdocs/geraci.pdf titled  Nanotechnology: Collaboration Opportunities for Workplace Safety. Chuck  noted that NIOSH has a long history of working in the “gray zone”, using  experience-based approaches which adapt existing frameworks to new  situations by focusing on what may be unique.  He emphasized that  regulators and industry share responsibility for occupational safety and  health, and provided a thorough review of opportunities to collaborate  with NIOSH on worker health and safety issues.  Next, Dr. Kristen M.  Kulinowski, Center for Biological and Environmental Nanotechnology,  International Council on Nanotechnology, Rice University, walked through  a PowerPoint presentation, available online, http://www.enobis.com/pdfdocs/kulinowski.pdf titled Collaboration on Nanotechnology Workplace Safety: Tools for Nano  Businesses.  Kristen’s presentation summarized key issues with respect  to collecting reliable information on workplace nano hazards, and  explained an extremely useful tool for business – the GoodNanoGuide, http://GoodNanoGuide.org – an Internet site which presents specific practices for safe handling  of nanomaterials by workers or researchers. This is a  community-generated site, and NbA members are encouraged to become both  users and contributors.
Next, Lynn L. Bergeson, Bergeson & Campbell, P.C., a Washington,  D.C. law firm, provided a PowerPoint presentation, available online, http://www.enobis.com/pdfdocs/bergeson.pdf titled Effectively Navigating Your Business around Uncertainties:  Making the Most from Careful Planning, Regulatory Awareness, and Smart  Planning.  The presentation expressed the reasons why NbA members must  engage early and often with regulators, legislators, and health and  environment public interest groups to ensure businesses’ message is  clear, its commitment to stewardship is known, and its science is  understood.
Richard Canady, PhD DABT, Senior Advisor, McKenna, Long &  Aldridge, LLP, next went through a PowerPoint presentation, available  online, http://www.enobis.com/pdfdocs/canady.pdf titled The  Evolving Regulatory Landscape for Nanomaterials.  The presentation  summarized the preceding presentations, pointed out that both legal  requirements and regulatory philosophies vary both across and within  agencies, reiterated that NbA members need to engage with government  officials and present businesses’ views on responsible commercialization  of nanotechnology. For example, he noted most nanomaterials safety  studies to date have looked at hazards but not assessed exposure risks.  Businesses could advocate for safety studies which more accurately  reflect actual or proposed uses.
The final panel, moderated by Philip Lippel, PhD, was titled  Advising the NNI-NGO Input to Research Priorities and Regulatory Issues:  The Roles of the National Nanotechnology Advisory Panel and the  National Academies of Sciences.  Terry L. Medley, Global Director,  Corporate Regulatory Affairs, DuPont, provided a PowerPoint  presentation, available online, http://www.enobis.com/pdfdocs/medley.pdf on the recently concluded Third Assessment of the National  Nanotechnology Initiative by the President’s Council of Advisors on  Science and Technology. Terry offered his insights on the PCAST review  process, discussed the summary recommendations, and speculated about  their impact on future directions of the National Nanotechnology  Initiative. (The full Report to the President and Congress… http://www.whitehouse.gov/sites/default/files/microsites/ostp/pcast-nano-report.pdf is now available from the Office of Science and Technology Policy.)   Terry serves as a member of the Nanotechnology Working Group of the  President’s Council of Advisors on Science and Technology (PCAST), which  authored the report.
Next, NbA was pleased to hear the remarks of Dr. Jennifer Sass,  Senior Scientist, Natural Resources Defense Council (NRDC), and also a  member of the PCAST Nanotechnology Working Group.  Dr. Sass provided an  overview of NRDC’s interest in nanotechnology and its perspective as a  very large non-governmental organization (NGO).
Following Dr. Sass, Ray Wassel, Senior Program Officer, Board of  Environmental Studies and Toxicology, National Research Council (NRC),  described work just getting underway, under EPA sponsorship, to develop a  research strategy for environmental, health, and safety aspects of  engineered nanomaterials. Further information on this 4-year project,  with an interim report due late next year, is available on the National  Academies’ website. http://www8.nationalacademies.org/cp/projectview.aspx?key=49173
The afternoon keynote slot featured Anne Meagher Northup,  Commissioner, Consumer Product Safety Commission (CPSC),who offered her  perspective of the CPSC’s role in ensuring consumer products are safe.  She discussed the Commission’s challenges given the scope of its  mandate, and its plans for discharging its responsibilities.
Following Commissioner Northup’s remarks, Lloyd Whitman, Deputy  Director, Center for Nanoscale Science & Technology, National  Institute of Standards and Technology (NIST), U.S. Department of  Commerce, gave a PowerPoint presentation, available online, http://www.enobis.com/pdfdocs/whitman.pdf titled Supporting the Nanotechnology Enterprise from Discovery to  Production.  The presentation emphasized that industry receives high  priority in using CNST’s advance resources for fabricating and  characterizing nanomaterials, in line with NIST’s mission to support  U.S. innovation and industrial competitiveness.
The final presentation of the day, available online, http://www.enobis.com/pdfdocs/murday.pdf was given by Dr. James S. Murday, Director of Physical Sciences,  University of Southern California. Jim reported on an NSF Sponsored  Workshop: Partnership for Nanotechnology Education at the University of  Southern California. His presentation provided an overview of why  creating partnerships for nanotechnology education is an excellent way  to promote nanotechnology and ensure its sustainability. Jim urged the  nanotechnology community to become involved in efforts to develop  uniform science education standards, noting that due to current reform  efforts, we may have a unique opportunity over the next year to make  students better prepared for careers in nanotechnology.
The Federal Roundtable provided an invaluable opportunity to meet  many of the key government and other stakeholder representatives engaged  in policy and regulatory initiatives directly relevant to NbA members,  to hear about these critically important developments, and to engage  with these stakeholders in a casual business setting.  The Federal  Roundtable accomplished our goals set for the NbA, and we look forward  to another roundtable in 2011.
Regards,
Vincent Caprio “It’s Green, It’s Clean, It’s Never Seen – That’s  Nanotechnology”
www.vincentcaprio.org
Executive Director
NanoBusiness Alliance
203-733-1949
vincentcaprio@nynanobusiness.org